Welcome to our dedicated page for Cargo Therapeutics SEC filings (Ticker: CRGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CARGO Therapeutics Inc. filings document the transition of a Nasdaq-listed biotechnology issuer from operating-company reporting through acquisition, exchange delisting, and Exchange Act deregistration. Its records include Form 8-K disclosures on the completed tender offer and merger process with Concentra Biosciences, common-stock and contingent value right consideration, material agreements, lease-assignment matters, and governance actions.
Additional filings cover annual stockholder voting, director elections, auditor ratification, Nasdaq Form 25 removal of CRGX common stock from listing and registration, and Form 15 termination or suspension of reporting obligations under the Exchange Act.
CARGO Therapeutics, Inc. (CRGX) – Form 4 filing
The filing discloses that director Abraham Bassan received a stock-option grant for 25,000 shares of CRGX common stock on 18 June 2025. The option carries an exercise price of $4.35 and will expire on 17 June 2035.
Vesting is 100% on the earlier of (i) the one-year anniversary of the grant date or (ii) the next annual shareholders’ meeting, contingent upon continued service. No shares were sold or otherwise disposed of; Bassan’s beneficial ownership now includes the 25,000 unexercised options, recorded as directly held.
The transaction appears to be a routine equity incentive designed to align director interests with those of shareholders. There are no accompanying cash transactions, sales, or changes in ownership structure noted in this filing.
CARGO Therapeutics, Inc. (CRGX) – Form 4 insider filing dated 06/20/2025
The filing discloses a single equity-based transaction involving Director Kapil Dhingra. On 06/18/2025, Dr. Dhingra was granted a stock option for 25,000 common shares with an exercise price of $4.35 per share. The option vests 100 % on the earlier of (i) the one-year anniversary of the grant date or (ii) the next annual shareholder meeting, provided the director continues to serve the company. The option expires on 06/17/2035. After this grant, Dr. Dhingra now holds 25,000 derivative securities (options) directly.
No non-derivative share transactions were reported, and there were no sales or exercises associated with the option. The transaction was reported on a Form 4 filed by one reporting person; no 10b5-1 trading plan box was checked. The filing represents routine director compensation rather than an open-market purchase or sale.
For investors, the disclosure indicates additional potential dilution of up to 25,000 shares (≈0.1 % of a typical small-cap biotech float) should the option be exercised, while also aligning the director’s incentives with long-term shareholder value via equity compensation.
CARGO Therapeutics, Inc. (CRGX) – Form 4 filing dated 20 June 2025
The filing discloses that non-employee director David Charles Lubner received a routine equity incentive on 18 June 2025: a stock option for 25,000 shares of common stock with an exercise price of $4.35 and an expiration date of 17 June 2035. All 25,000 options will vest 100 % on the earlier of (i) the one-year anniversary of the grant date or (ii) the company’s next annual meeting, conditional upon the director’s continued service. Following this grant, Mr. Lubner beneficially owns 25,000 derivative securities, held directly. No open-market purchases, sales, or changes to non-derivative share ownership were reported.
Because the filing represents a standard board option grant, it does not alter the company’s capital structure or signal insider buying or selling of common shares. The information is therefore operationally routine and financially immaterial for most investors, though it demonstrates continued alignment of director incentives with shareholder value.
CARGO Therapeutics, Inc. (CRGX) filed a Form 4 disclosing a routine equity award to director Jane Henderson.
On 18 June 2025, Henderson received a stock option covering 25,000 common shares with an exercise price of $4.35. The option vests 100 % on the earlier of (i) 18 June 2026 or (ii) the company’s next Annual Meeting, contingent on her continued board service. The instrument carries a 10-year term, expiring 17 June 2035. Following the grant, Henderson’s beneficial ownership of derivative securities totals 25,000 options; no non-derivative share transactions were reported.
The filing is noted as a single-person submission, confirms Henderson’s status solely as a director, and contains no indication of a Rule 10b5-1 trading plan. No sales, purchases, or other equity movements were disclosed beyond this compensatory award.